 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
27 News |  |
- | ALG.APV-527 / Alligator Biosci, Medexus
Preclinical, Journal: The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies. (Pubmed Central) - Nov 8, 2022
ALG.APV-527 is uniquely designed for 5T4-conditional 4-1BB-mediated anti-tumor activity with potential to minimize systemic immune activation and hepatotoxicity while providing efficacious tumor-specific responses in a range of 5T4-expressing tumor indications as demonstrated by robust activity in preclinical in vitro and in vivo models. Based on the combined preclinical dataset, ALG.APV-527 has potential as a promising anti-cancer therapeutic for the treatment of 5T4-expressing tumors.
- || ALG.APV-527 / Alligator Biosci, Medexus
$APVO Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND https://t.co/LSZajdYddX (Twitter) - Sep 19, 2022
- ALG.APV-527 / Alligator Biosci, Medexus
ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1122;
The unique design of the molecule minimizes systemic immune activation and hepatotoxicity, allowing for highly efficacious tumor-specific responses as demonstrated by potent activity in in vitro models. Based on these preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors and is progressing towards a phase I clinical trial in 2021.
- ALG.APV-527 / Alligator Biosci, Medexus, urelumab (BMS-663513) / BMS, Ono Pharma
[VIRTUAL] Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2075;
APV-527 induces potent CD8+ T cell and NK cell co-stimulation and T-cell cytotoxicity and has potent in vivo anti-tumor activity, without inducing systemic toxicity. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors.
- ALG.APV-527 / Alligator Biosci, Medexus, urelumab (BMS-663513) / BMS, Ono Pharma
[VIRTUAL] Potent tumor-directed T cell activation and in vivo tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody (virtual poster hall) - Nov 3, 2020 - Abstract #SITC2020SITC_2011;
APV-527 induces potent CD8+ T cell and NK cell co-stimulation and T-cell cytotoxicity and has potent in vivo anti-tumor activity, without inducing systemic toxicity. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors.
- ALG.APV-527 / Alligator Biosci, Aptevo
Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIR™ bispecific antibody (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1000;
ALG.APV-527 induces 5T4-dependent CD8+ T cell and NK co-stimulation, and has potent anti-tumor activity in a therapeutic model. Based on preclinical data, ALG.APV-527 is a promising anti-cancer therapeutic for the treatment of a variety of 5T4-expressing solid tumors.